These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 22339457)

  • 1. Conference scene: recent advancements in microscale bioprocess development.
    Guy H
    Immunotherapy; 2012 Feb; 4(2):145-7. PubMed ID: 22339457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conference scene: miniaturisation - micro scale bioprocess development.
    Chiverton LM
    Immunotherapy; 2011 Jan; 3(1):13-6. PubMed ID: 21174552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous bioprocessing: the real thing this time? 10(th) Annual bioProcessUK Conference, December 3-4, 2013, London, UK.
    Farid SS; Thompson B; Davidson A
    MAbs; 2014; 6(6):1357-61. PubMed ID: 25484060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biopharmaceuticals in China.
    Hu X; Ma Q; Zhang S
    Biotechnol J; 2006 Nov; 1(11):1215-24. PubMed ID: 17089435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microtools for single-cell analysis in biopharmaceutical development and manufacturing.
    Love KR; Bagh S; Choi J; Love JC
    Trends Biotechnol; 2013 May; 31(5):280-6. PubMed ID: 23582471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioprocessing in the Digital Age: The Role of Process Models.
    Narayanan H; Luna MF; von Stosch M; Cruz Bournazou MN; Polotti G; Morbidelli M; Butté A; Sokolov M
    Biotechnol J; 2020 Jan; 15(1):e1900172. PubMed ID: 31486583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The challenges of product- and process-related impurities to an evolving biopharmaceutical industry.
    Bracewell DG; Smales CM
    Bioanalysis; 2013 Jan; 5(2):123-6. PubMed ID: 23330553
    [No Abstract]   [Full Text] [Related]  

  • 8. Russia through the prism of the world biopharmaceutical market.
    Bairamashvili DI; Rabinovich ML
    Biotechnol J; 2007 Jul; 2(7):801-17. PubMed ID: 17615600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Manufacturing, regulatory and commercial challenges of biopharmaceuticals production: a Finnish perspective.
    Närhi M; Nordström K
    Eur J Pharm Biopharm; 2005 Apr; 59(3):397-405. PubMed ID: 15760720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second International Conference on Accelerating Biopharmaceutical Development: March 9-12, 2009, Coronado, CA USA.
    Reichert JM; Jacob N; Amanullah A
    MAbs; 2009; 1(3):190-209. PubMed ID: 20065637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-Throughput Process Development for Biopharmaceuticals.
    Shukla AA; Rameez S; Wolfe LS; Oien N
    Adv Biochem Eng Biotechnol; 2018; 165():401-441. PubMed ID: 29134461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in capacity utilization for therapeutic monoclonal antibody production.
    Langer ES
    MAbs; 2009; 1(2):151-6. PubMed ID: 20061821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additive Biotech-Chances, challenges, and recent applications of additive manufacturing technologies in biotechnology.
    Krujatz F; Lode A; Seidel J; Bley T; Gelinsky M; Steingroewer J
    N Biotechnol; 2017 Oct; 39(Pt B):222-231. PubMed ID: 28890405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medium to high throughput screening: microfabrication and chip-based technology.
    Wen Y; Zhang X; Yang ST
    Adv Exp Med Biol; 2012; 745():181-209. PubMed ID: 22437819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microscale bioprocess optimisation.
    Micheletti M; Lye GJ
    Curr Opin Biotechnol; 2006 Dec; 17(6):611-8. PubMed ID: 17084609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multivariate PAT solutions for biopharmaceutical cultivation: current progress and limitations.
    Mercier SM; Diepenbroek B; Wijffels RH; Streefland M
    Trends Biotechnol; 2014 Jun; 32(6):329-36. PubMed ID: 24732022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conference scene: taking the heat out of chaperokine function.
    Gazali A
    Immunotherapy; 2012 Aug; 4(8):773-5. PubMed ID: 22947004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The therapeutic antibodies market to 2008.
    Pavlou AK; Belsey MJ
    Eur J Pharm Biopharm; 2005 Apr; 59(3):389-96. PubMed ID: 15760719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hybrid modeling for quality by design and PAT-benefits and challenges of applications in biopharmaceutical industry.
    von Stosch M; Davy S; Francois K; Galvanauskas V; Hamelink JM; Luebbert A; Mayer M; Oliveira R; O'Kennedy R; Rice P; Glassey J
    Biotechnol J; 2014 Jun; 9(6):719-26. PubMed ID: 24806479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards a widespread adoption of metabolic modeling tools in biopharmaceutical industry: a process systems biology engineering perspective.
    Richelle A; David B; Demaegd D; Dewerchin M; Kinet R; Morreale A; Portela R; Zune Q; von Stosch M
    NPJ Syst Biol Appl; 2020 Mar; 6(1):6. PubMed ID: 32170148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.